ArriVent BioPharma, Inc. Common StockAVBPNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+55.2%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+55.2%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
3.7x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$24.18M+58.0%
2024$15.30M+57.7%
2023$9.71M+49.9%
2022$6.47M+186.2%
2021$2.26M-